Ascendis Pharma (ASND) Tops Q4 EPS by 37c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR1.54), EUR0.37 better than the analyst estimate of (EUR1.91). Revenue for the quarter came in at EUR137.7 million versus the consensus estimate of EUR85.87 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• UBS Reiterates Sell Rating on Macy's (M) on Price Challenges Vs. Peers
• Intuit holds investor day, reaffirms fiscal 2027 guidance